Menu Search
Equities

Genscript Biotech Corp

G51:STU

Genscript Biotech Corp

Actions
  • Price (EUR)1.27
  • Today's Change-0.10 / -7.30%
  • Shares traded0.00
  • 1 Year change-55.28%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Genscript Biotech Corp grew revenues 34.17% from 625.70m to 839.53m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -226.85m to -95.48m.
Gross margin53.63%
Net profit margin-32.19%
Operating margin-28.02%
Return on assets-9.68%
Return on equity-13.78%
Return on investment-14.76%
More ▼

Cash flow in USDView more

In 2023, Genscript Biotech Corp increased its cash reserves by 41.25%, or 422.40m. Cash Flow from Financing totalled 1.07bn or 127.25% of revenues. In addition the company used 286.91m for operations while cash used for investing totalled 357.73m.
Cash flow per share-0.9051
Price/Cash flow per share--
Book value per share4.44
Tangible book value per share4.38
More ▼

Balance sheet in USDView more

Genscript Biotech Corp has a Debt to Total Capital ratio of 19.72%, a lower figure than the previous year's 24.82%.
Current ratio4.15
Quick ratio4.06
Total debt/total equity0.3689
Total debt/total capital0.1972
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.